ArticleBriefings in bioinformatics2025
MOFormer: navigating the antimicrobial peptide design space with Pareto-based multi-objective transformer.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Next-Generation Antimicrobial Peptides for Biofilm-Associated Infections: Engineering, Biomaterial Delivery and AI-Assisted Discovery.Antibiotics (Basel, Switzerland) · 2026Review
- Generative AI for controllable protein sequence design: A survey.npj drug discovery · 2026Review
- Article
- Artificial intelligence for antimicrobial resistance: advancing reproducibility, interpretability, and clinical deployment.Briefings in bioinformatics · 2026Review
- Antimicrobial Peptides as Cross-Seeding Modulators at the Neurodegenerative-Infectious Interface.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Antimicrobial peptide (AMP) design through deep learning holds the potential to revolutionize antibiotic development. Despite recent progress in AMP generation, designing peptide antibiotics with multiple optimal properties remains a significant challenge. We present MOFormer, an advanced multi-objective AMP design pipeline capable of optimizing multiple AMP properties simultaneously. By leveraging a conditional Transformer, the model refines the AMP sequence-property landscape for efficient multi-objective generation. It also incorporates regularization techniques to maintain a highly structured space, enabling the sampling of precise and desirable candidates. Comparative analyses reveal that MOFormer achieves the optimal hypervolume in the multi-objective space, surpassing advanced methods in simultaneously maximizing antimicrobial activity (minimum inhibitory concentration) and minimizing hemolysis and toxicity, thereby yielding the most promising and desirable set of candidate peptides. When extended to a tri-objective scenario, MOFormer continues to exhibit remarkable optimization performance. Finally, we execute a hierarchical and rapid ranking of generated candidates based on Pareto fronts. We conducted a comprehensive validation of the physicochemical properties and target attributes of the candidates, while AlphaFold structure predictions revealed notably reliable predicted local distance difference test scores ranging from 70% to 87%. Our findings suggest that MOFormer holds potential to accelerate the discovery of efficacious peptide antibiotics by optimizing multi-objective trade-offs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.